Tag:
Endocyte
Latest Headlines
Latest Headlines
Readers' picks, responses to Fierce's 'Top 10' cancer drugs report
I've tried to capture some of the most interesting responses we've gotten over the past few days since we published our 2012 report .
Merck snags rights to Endocyte's ovarian cancer drug in $1B deal
Merck has scooped up worldwide rights to Endocyte's late-stage ovarian cancer drug in a billion-dollar deal.
J&J's chemo drug shortage hits Amgen, Lilly, Endocyte trials
Got Doxil? Not only are thousands of patients waiting for their doses of the chemo drug, there's a long list of drug developers in need of Doxil for clinical trials of experimental therapies.
"Lilly effect" helps drive a life sciences boom in Indiana
Call it the "Lilly effect." The Wall Street Journal mapped out several places in America which have thrived in spite of a sour economy and quickly zeroed in on Indiana's booming life sciences
Endocyte shares spike on plan to seek early approval for lead cancer drug
Shares of Endocyte ( $ECYT ) shot up 25 percent on Tuesday after the Indiana biotech announced that it plans to push ahead with an application for conditional European approval of its lead drug for
Biotechs braving stormy IPO waters to raise cash
A pair of life sciences companies which went public on Friday morning saw their shares surge upward in the afternoon. But the gains came only after each had chopped a huge chunk off their projected
Endocyte readies $86M IPO for chilly market
Yet another biotech company with no product revenue and an abundance of risk is preparing to dive into chilly market waters. In this case the undaunted Endocyte, a developer relying on its platform
